FGF23 and metabolic syndrome: They detected elevated levels of FGF-23 in bone after MetS establishment, which subsequently led to significant bone loss, with alterations of bone histomorphometric parameters characterized by increased osteoclastic activity and decreased osteoblastic activity (35).